Recurrent Lung Non-Small Cell Carcinoma Clinical Trials

12 recruiting

Recurrent Lung Non-Small Cell Carcinoma Trials at a Glance

12 actively recruiting trials for recurrent lung non-small cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Seattle, Columbus, and Washington D.C.. Lead sponsors running recurrent lung non-small cell carcinoma studies include SWOG Cancer Research Network, Dwight Owen, and University of Washington.

Browse recurrent lung non-small cell carcinoma trials by phase

Treatments under study

About Recurrent Lung Non-Small Cell Carcinoma Clinical Trials

Looking for clinical trials for Recurrent Lung Non-Small Cell Carcinoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Lung Non-Small Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Lung Non-Small Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled344 locationsNCT03191149
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell Carcinoma+24 more
Mayo Clinic324 enrolled3 locationsNCT06349642
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Phase 1

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
Dwight Owen24 enrolled1 locationNCT06616623
Recruiting
Phase 1

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+2 more
Dwight Owen30 enrolled1 locationNCT05234307
Recruiting
Phase 2Phase 3

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network378 enrolled361 locationsNCT06616584
Recruiting
Phase 2

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network56 enrolled267 locationsNCT06031688
Recruiting
Not Applicable

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
University of Washington80 enrolled1 locationNCT04151940
Recruiting
Phase 2

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network66 enrolled448 locationsNCT05642572
Recruiting
Phase 2

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
University of Washington30 enrolled1 locationNCT05570825
Recruiting
Phase 1

MOv19-BBz CAR T Cells in FRa+ Cancers

Recurrent Lung Non-Small Cell CarcinomaMetastatic Non Small Cell Lung Cancer
University of Pennsylvania10 enrolled1 locationNCT07116057